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MYOCYTE CONTRACTILE 
PROCESSES 
Insights into mechanisms 
of action 
Administration of 3,5,3'-triiodo-L-thyronine (3"3) has recently been suggested 
to acutely improve l ft ventricular performance. However, the cellular and 
molecular mechanisms responsible for this improvement in left ventricular 
function with T 3 remained unknown. Accordingly, the present study examined 
the direct effects of T a administration on myocyte contractile function and the 
sarcolemmal systems that might potentially contribute to these effects. In 
isolated porcine l ft ventricular myocytes (n = 81), velocity of shortening 
increased in the presence of 80 pmol/L T 3 compared with that in untreated 
myocytes (117.0 - 5.0 versus 77.3 - 3.3 lam/sec, p < 0.05). In a separate series 
of experiments (n = 29), myocyte velocity of shortening increased in the 
presence of both T a and/3-adrenergic receptor stimulation (25 nmol/L isopro- 
terenol) to greater than that with /]-adrenergic receptor stimulation alone 
(274.3 -+ 16.9 versus 203.7 +- 16.2 ~m/sec, p < 0.05). Cyclic adenosine 
monophosphate g neration was next examined in isolated myocyte prepara- 
tions (n = 9). In the presence of To, no significant increase in cyclic-adenosine 
monophosphate generation was observed compared with that in untreated 
myocytes (39.1 - 8.3 versus 24.7 +- 5.8 fmols/myocyte, p = 0.17). However, in 
the presence of both T 3 and /]-adrenergic receptor stimulation, cyclic-ade- 
nosine monophosphate g neration increased ignificantly to greater than that 
with/3-adrenergic receptor stimulation alone (224.4 - 61.1 versus 120.1 - 35.5 
fmoles/myocyte, p < 0.05). Because cyclic-adenosine monophosphate modu- 
lates intracellular Ca +2 processes, L-type Ca +2 channel current (patch clamp 
methods; -picoamp/picofarad, n -- 15) and peak intracellular Ca +2 levels 
(fura 2 ionic measurement,  = 47) were next measured. In the presence of To, 
a shift in the activation voltage at peak L-type Ca +2 channel current was 
observed from baseline (5.5 - 1.4 versus 9.0 -+ 1.0 mV, p < 0.05). Furthermore, 
in the presence of both T a and/]-adrenergic receptor stimulation, peak L-type 
Ca +2 channel current (8.9 -+ 0.7 versus 6.3 - 1.0 mV, p < 0.05) and peak intra- 
cellular Ca +2 levels (189.9 - 8.4 versus 171.7 -+ 8.3 nmol/L,p < 0.05) increased 
compared with values obtained with ~-adrenergic receptor stimulation alone. 
Important findings from the present study were twofold: (1) T a improved 
myocyte contractile processes through a cyclic-adenosine monophosphate- 
independent mechanism and (2) T 3 potentiated the effects of ~-adrenergic 
receptor stimulation transduction by increasing cyclic-adenosine monophos- 
phate production, L-type Ca +2 channel current, and Ca +2 availability to the 
myocyte contractile apparatus. Thus T3 may provide a clinically useful adjunct 
to /]-adrenergic agonist therapy. (J THORAC CARD~OVASC SURG 1995;110: 
1369-80) 
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T he active form of thyroid hormone, 3,5,3'-triiodo- L-thyronine (T3), significantly contributes to car- 
diovascular performance. 1 A chronic elevation in 
the circulating level of T 3 causes an increase in heart 
rate and cardiac output and a decrease in systemic 
vascular esistance. 25 In animal models, alterations 
in contractile protein expression and synthesis have 
been demonstrated to occur with persistent eleva- 
tions in circulating T 3 levels. 6-!° Finally, increased 
circulating levels of T 3 have been shown to augment 
oxygen consumption and increase rate of tension 
development in isolated papillary muscles. 2'1~'12 
Although these effects of chronic elevation in the 
circulating levels of T 3 on cardiovascular perfor- 
mance are well established, the effects of a single 
acute administration of T 3 on fundamental contrac- 
tile processes are incompletely understood. Past 
reports have suggested that acute administration of 
T 3 improves cardiac output after cardiopulmonary 
bypass.~3, 14 Recently, this laboratory has demon- 
strated that acute administration of T 3 has direct 
and beneficial effects on isolated left ventricular 
(LV) myocyte contractile performance. 15' 16 How- 
ever, the underlying mechanisms for the beneficial 
effects of a single administration of T 3 on myocyte 
contractile function remain unknown. Accordingly, 
the overall goal of the present project was to deter- 
mine the acute effects of T 3 on myocyte sarcolemmal 
processes and to relate these effects to changes in 
myocyte contractile function. 
Past reports have demonstrated that elevation in 
the circulating level of T3 can cause increased 
contractile protein messenger ribonucleic acid ex- 
pression over a period of days. s' 9, 17-19 In a recent 
report from this laboratory, a 2-hour exposure to a 
single dose of T 3 improved myocyte contractile 
function and /3-adrenergic responsiveness. 16 Thus 
the acute and direct effects of T 3 on myocyte 
contractile function and /3-adrenergic responsive- 
ness that were observed in our recent studies were 
probably not caused by an alteration in contractile 
protein content. Several past reports have demon- 
strated that T 3 can directly modulate cell membrane 
enzyme systems. 2°-2s For example, the density and 
hydrolytic activity of the Na+,K+-adenosinetriphos - 
phatase (ATPase) system has been shown to be 
altered in the presence of T3 .26-2s It has also been 
demonstrated that T3 influences jg-adrenergic recep- 
tor density and transduction. 21-23 Finally, T 3 regula- 
tion of intrace!lular Ca +2 by sarcolemmal Ca ÷2- 
ATPase activity has been reported. 24 Taken 
together, these past studies suggest that T 3 may act 
directly at the level of the myocyte sarcolemma. 
Therefore the present study was designed to test the 
hypothesis that the mechanism for the acute effects 
of T 3 on myocyte contractile function is a direct 
effect on myocyte sarcolemmal transduction sys- 
tems. 
Methods 
Experimental design and rationale. The objective of 
the present study was to examine representative sarcolem- 
mal systems that may be immediately affected by exposure 
to T3- The /3-adrenergic receptor system located on the 
myocyte sarcolemma is an important mediator of intracel- 
lular events that directly influence myocyte contractile 
performance.29, 30 Activation of the/3-adrenergic re eptor 
system results in production of cyclic adenosine mono- 
phosphate (cAMP). z9' 3o In light of the fact that T 3 may 
influence the activity of the/3-adrenergic re eptor system, 
cAMP production was measured in isolated myocytes at 
baseline and after T 3 administration,/3-adrenergic ecep- 
tor stimulation, or both. 
Another important sarcolemmal system that modulates 
myocyt e contractile performance is the Na+~K+-ATPase 
system. This sarcolemmal receptor transports three Na ~ 
ions out of the myocyte and two K + ions into the myocyte 
for each ATP molecule hydrolyzed. 3°' 31 Previous reports 
have suggested that T 3 may influence Na+,K+-ATPase 
hydrolyti c activity. 26-28 Accordingly, sarcolemmal prepa- 
rations were used to measure the acute effect of T 3 on 
Na+,K+-ATPase hydrolytic activity. 
A third important sarcolemmal receptor system, the 
L-type Ca +2 channel, is responsible for triggering the 
release of intracellular Ca +2 within the cytoplasmic space 
of the myocyte. The L-type Ca +2 channel can be phos- 
Phorylated by cAMP-mediated events, which in turn can 
increase the contractile state of the myocyte. 32 Previous 
reports from this laboratory demonstrated that in the 
presence of T3, myocyte/3-adrenergic responsiveness was 
significantly increased, is' 16 This increased contractile re- 
sponse may be a result in part of augmentation f L-type 
Ca +2 channel current density. Accordingly, the present 
study examined the effects on L-type Ca +2 channel cur- 
rent density of acute treatment wit h T3, /3-adrenergic 
receptor stimulation, or both. 
A final common pathway that results from activation of 
the/3-adrenergic re eptor system, modulation of Na+,K ÷- 
ATPase activity, or enhanced L-type Ca +z channel cur- 
rent density is increased intracellular Ca +z within the 
myocyte. 29-32 Therefore, in a final set of experiments, 
changes in intracellular ca +; content were directly mea- 
sured in isolated myocytes after exposure to T3,/3-adren- 
ergic stimulation, or both. 
Experimental design: myocyte isolation and contractile 
function measurement. Six pigs (Yorkshire strain, 28 kg) 
were anesthetized with isoflurane (0.5%/1.5 L per minute) 
and the lungs ventilated through a nonrecirculating anes- 
thesia circuit. A stern0tomy was done and the heart was 
quickly extirpated and placed in an oxygenated Krebs 
solution. The region of the LV free wall containing the left 
circumflex coronary artery was dissected free, the artery 
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was cannulated, and the tissue was prepared for myocyte 
isolation. All animals were treated and cared for in 
accordance with the National Institutes of Health Guide 
for the Care and Use of Laboratory Animals9 With the 
use of methods described by this laboratory previ- 
ously, 34-36 Krebs solution containing collagenase (0.5 mg/ 
ml, type II; 146 U/mg, Worthington, Pa.) was perfused 
through the circumflex artery. The tissue was then minced 
and triturated with 400 ixmol/L CaC12 and collagenase 
(0.5 mg/ml). After filtration of the supernatant, the cells 
were allowed to settle and the myocyte pellet was resus- 
pended in standard culture medium (medium 199, nutri- 
ent mixture F-12, 2 mmol/L Ca 2+, Gibco Laboratories, 
Grand Island, N.Y.). 
Myocyte contractile function was examined under the 
following conditions: (1) basal state (no T3, no isoproter- 
enol), (2) in the presence of 80 pmol/L T3, (3) in the 
presence of 25 nmol/L isoproterenol, and (4) in the 
presence of both 80 pmol/L T 3 and 25 nmol/L isoproter- 
enol. Video-assisted microscopy techniques described 
previously were used. 34-36 The concentration fT 3 used in 
the present study was based on the results of previous 
dose-response tudies done in this laboratory] 5 T 3 was 
dissolved in NaOH and subsequently diluted to a concen- 
tration of 80 pmol/L T z with standard culture medium 
such that the final concentration of NaOH was 2 × 10 7 
mol/L. Thls concentration of NaOH had no effect on 
myocyte contractile processes. The concentration of the 
nonselective/3-adrenergic a onist, isoproterenol, was also 
chosen on the basis of findings O f previous dose-response 
studies done in this laboratory. 37 Myocytes were imaged 
on an inverted microscope (Axiovert IM35, Zeiss Inc., 
Oberkochen, Germany) in a 2.5 cc tissue chamber with a 
thermoregulator to maintain the media temperature at 
37 ° C. The oxygen tension of the medium was maintained 
at greater than 400 mm Hg throughout the experimental 
protocol. Myocytes were stimulated at 1 Hz and contrac- 
tions were: imaged with use of a charge-coupled device 
(GPCD60, Panasonic, Secaucus, N.J.). Myocyte motion 
signals were input through an edge detector system (Cres- 
cent Electronics, Sandy, Utah), converted into a voltage 
signal, digitized, and input to a computer (80286, 
ZBV2526, Zenith Data Systems, St. Joseph, Mich.) for 
subsequent analysis. 34-36 Stimulated myocytes were al- 
1owed a 5,minute stabilization period after which con- 
traction data for each myocyte were recorded from a 
minimum of 20 consecutive contractions. Parameters 
computed from the digitized contraction profiles included 
percentage shortening (percent), peak velocity of short- 
ening (micrometers per second), peak velocity of length- 
ening (micrometers per second), total contraction 
duration (milliseconds), and time to peak contraction 
(milliseconds). Contractile measurements were obtained 
only on those myocytes that maintained a long-axis orien- 
tation perpendicular tothe microscope objective through- 
out the contraction profile. 
Measurement of cAMP content. Isolated myocytes 
(12,500 cel!s/0.5 ml) were incubated at 37 ° C in medium 
for 10 minutes under the following conditions: (1) basal 
state (no T3, no isoproterenol), (2) in the presence of 80 
pmol/L T3, (3) in the presence of 25 nmol/L isoproterenol, 
and (4) in the presence of both 80 pmol/L T3 and 25 
nmol/L isoproterenol. Adenylate cyclase activity was de- 
termined by timed cAMP production with use of previ- 
ously described methods. 37' 3s Reactions were terminated 
by placing the tubes in an ice-cold bath followed by 
centrifugation at 3250 g for 5 minutes. Pellets were 
resuspended in 0.5 ml buffer (50 mmol/L Tris-HCL, 10 
mmol/L MgC12, 10 /xmol/L egtazic acid, 10 /xmol/L phe- 
nylmethylsulfonylacid, 2.8/xmol/L egtazic acid), boiled for 
5 minutes, and then centrifuged at 6500 g for 10 minutes. 
The supernatant was assayed for cAMP content with use 
of a competitive radiolabeled assay (RIA Kit, Advanced 
Magnetics Inc., Cambridge, Mass.), Adenylate cyc!ase 
activity was determined at baseline, with T3, with /3-ad- 
renergic receptor stimulation, and in the presence of both 
T3 and fl-adrenergic receptor stimulation. Results were 
expressed as picomoles per liter cAMP produced/12,500 
cells per 10 minutes. All measurements were done in 
duplicate. 
Na+,K÷-ATPase glycoside binding and hydrolytic ac- 
tivity. Sarcolemmal membranes were prepared from the 
harvested porcine LVs as previously describedS' 39 The 
effect of T 3 on Na+,K+-ATPase hydrolytic apacity was 
examined by assessing p-nitrophenol-phosphatase (p- 
NPPase) activity. 4° Previously frozen LV myocardial sam- 
ples were homogenized in 30 mmol/L histidine buffer (pH 
7.4) at a 4:1 mixture (volume/weight). The assay was run 
at 37 ° C with use of a 215 ixl aliquot of tissue homogenate 
in a reaction medium Containing (in final concentration) 
150 mmol/L KC1, 20 mmol/L MgC12, 30 mmol/L histidine 
(pH 7.4), 2 mmol/L egtazic acid, 10 mmol/L p-NPP (pH 
7.4), and 3.3% bovine serum albumin. A standard curve 
was established with use of serial concentrations of p- 
nitrophen01 read at 410 nm with a digital spectrophotom- 
eter (Spectronic 21D, Milton Roy Company, Belgium). 
Ouabain-sensitive p-NPPas e activity was determined by 
adding 10 mmol/L ouabain to reaction mixtures and 
subtracting these results from those obtained in the 
reaction mixtures without ouabain. The reaction was 
terminated after 30 minutes by the addition of 0.1 ml of 
50% trichloroacetic a id. Assays were run in duplicate and 
results were expressed as micrograms of p-nitrophenol 
released per milligram of protein per hour. Total protein 
concentration of tissue homogenates and sarcolemmal 
preparations were determined with the Bradford 41 assay. 
Measurement of L-type Ca +2 channel currents. 
Whole-cell L-type Ca +2 channel currents were measured 
by the whole-cell patch clamp methodJ 2 Isolated myo- 
cytes were placed in a 0.5 ml Lucite acrylic resin tissue 
chamber mounted on the stage of an inverted microscope 
(Diaphot, Nikon Instruments, Garden City, N.Y.) and 
superfused with a modified Kreb's solution containing (in 
millimoles per liter): NaC1 133, KC1 4.7, dextrose 16.5, 
HEPES 20, MgC12 1.2, and CaC12 2.5 (pH 7.44). Micro- 
electrodes (resistance 1.5 to 4 Mf~) were filled with 
pipette solution containing 100 /xg/ml nystatin (Sigma 
Chemical Co., St. Louis, No.). 43 After the formation of a 
gigaohm seal, when the patch was considered to be 
sufficiently permeabilized by nystatin, the superfusate 
solution was changed to an Na +- and K+-free solution 
that contained the following (in millimoles per liter): 
choline chloride 145, dextrose 5.5, MgC12 1.2, HEPES 5, 
CaC12 2.5, and 4-aminopyridine 2 (pH 7.2). All Ca +2 
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Table I. Acute effects of incubation with T 3 on 
myocyte function 
Isoproterenol, 
Steady state 25 nmol/L 
Percent shortening (%) 
No T3 5.3 ± 0.2 10.4 _+ 0.5* 
80 pmol/L T 3 7.0 --+ 0.3* 13.5 --+ 0.5*? 
Shortening velocity (/xm/sec) 
No T 3 77.1 _+ 3.3 203.7 +_ 16.2" 
80 pmol/L T 3 117.0 + 5.0? 274.3 + 16.9"? 
Lengthening velocity (/xm/sec) 
No T 3 86.2 _+ 5.3 194.3 _+ 17.8" 
80 pmol/L T 3 130.8 -+ 7.6? 260.3 _+ 23.5*? 
Time to peak contraction (msec) 
No T 3 232.1 _+ 7.0 194.0 ± 9.7* 
80 pmol/L T 3 215.6 + 6.8 184.6 ± 6.5* 
Duration of contraction (msec) 
No T 3 487.0 ± 12.6 425.5 _+ 27.8* 
80 pmol/L T 3 470.6 _+ 11.2 427.4 ± 22.9* 
No. of myocytes 
No T 3 81 29 
80 pmol/L T 3 71 28 
Values presented as mean plus or minus standard error of the mean. 
*p < 0.05 versus steady state. 
~'p < 0.05 versus no T3. 
channel currents were measured at room temperature 
(22 ° to 23 ° C) to enhance the temporal resolution of peak 
Ica measurements. Membrane voltage clamping protocols 
were generated with use of the pClamp software (version 
5.6, Axon Instruments, Burlingame, Calif.) and a 12-bit 
digital-to-analog convertor (LabMaster TL-1, Axon In- 
struments). To examine the current-voltage (I-V) rela- 
tionship for the L-type Ca +2 channels, the membrane 
holding potential was -40  mV.  42 Clamp steps from -50 
to +60 mV and 250 msec in duration were applied at 
5-second intervals. Inward currents were normalized to 
membrane capacitance. Current signals were low-pass 
filtered at 5 kHz and led to a whole-cell patch clamp 
amplifier (Axopatch 200A, Axon Instruments). The ana- 
log current and voltage signals were digitized at 12-bit 
resolution (LabMaster TL-1, Axon Instruments) and the 
digitized data were stored on a computer (Z433Dh, 
Zenith Data Systems). 
Parameters computed from the I-V relationship for 
peak L-type Ca 2÷ channel current included the maximum 
inward current and the membrane potential at which the 
Ca ÷2 channel current flow was maximal. The maximum 
inward current was computed to be the peak negative 
current from the !-V relationship. Measurements for each 
cell were made at baseline and in the presence of 80 
pmol/L T 3, of 25 nmol/L isoproterenol, or of both. 
Measurement of intraeellular Ca ÷z. Isolated myocytes 
were resuspended in indicator-free medium (Dulbecco's 
modified Eagle's medium, Gibco Laboratories, Life Tech- 
nologies, Inc., Grand Island N.Y.). Myocytes were studied 
under the following conditions: (1) basal state (no T3,  no  
isoproterenol), (2) in the presence of 80 pmol/L T3, (3) in 
the presence of 25 nmol/L isoproterenol, and (4) in the 
presence of both 80 pmol/L T 3 and 25 nmol/L isoproter- 
enol. Ten microliters of fura 2/acetomethoxy ester (50/zg 
fura 2, Molecular Probes, Inc., Eugene, Ore.; 50 /~1 
anhydrous dimethyl sulfoxide, Sigma) was added to the 
myocytes to yield a loading dye concentration of 5 
tzmol/L. Myocytes were allowed to equilibrate for 1 to 2 
hours in the dark before the experimental protocols were 
performed. Myocytes were studied in a thermostatically 
controlled chamber mounted on an Axiovert 35 inverted 
microscope (Zeiss). The microscope was interfaced to a 
spectrofluorometer and a digital fluorescence image anal- 
ysis system, Attoflur Ratio Vision (version 6.0, Atto 
Instruments, Rockville, Md.). Fluorescence missions 
were digitally collected at alternating excitation wave- 
lengths of 340 and 380 nmol/L. At the end of each 
experiment, background autofluorescence from the myo- 
cytes was digitally subtracted. The background signal was 
less than 1.5% of the total fluorescent signal from the fura 
2-loaded myocyte. The yield of viable myocytes after fura 
2 loading was 75% _+ 5%. Basal, peak, and timed aver- 
aged, steady-state intracellular Ca +2 measurements were 
recorded with a stimulation frequency of 30 pulses/min. 
The wavelength ratio was converted to an absolute Ca +2 
level with use of precalibrated analytical standards. 44
Data analysis. Indices of myocyte contractile function 
for the groups treated with and without T 3 were  compared 
by analysis of variance. For the /3-adrenergic response 
studies, measurements at baseline and after/3-adrenergic 
stimulation were directly compared by paired t test. In 
vitro assays for cAMP generation and L-type Ca +a chan- 
nel current density were compared for the treatment 
groups in a similar manner. Na+,K+-ATPase hydrolytic 
activity was analyzed by t test. For intracellular Ca ÷2 
measurements, a running average of 15 delivered stimuli 
was analyzed for each treatment by analysis of variance. 
After analysis of variance, mean separation was done with 
use of Bonferroni boundsY All statistical procedures 
were done with the BMDP statistical software package 
(BMDP Statistical Software Inc., Los Angeles, Calif.). 
Results are presented as mean plus or minus the standard 
error of the mean. Values ofp < 0.05 were considered to 
be statistically significant. 
Results 
Myocyte contractile function. In an initial series 
of experiments, the acute effects of T 3 on myocyte 
contracti le function were examined (Table 1). In the 
presence of T3, myocyte percent shortening in- 
creased by 32% and myocyte velocity of shortening 
increased by 52%. In the presence of  the 13-adren- 
ergic agonist isoproterenol ,  myocyte velocity of 
shortening increased by 164% (p < 0.05). More 
important , /3-adrenergic  st imulat ion after the addi- 
tion of T 3 increased myocyte velocity of shortening 
to values higher than those for isoproterenol  alone. 
Specifically, velocity of shortening in the presence of 
both T 3 and /3-adrenergic receptor  st imulat ion in- 
creased by an addit ional  34% compared  with that 
with 13-adrenergic st imulat ion alone (p < 0.05). 
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Thus, consistent with recent reports from this labo- 
ratory, T 3 improved indices of myocyte contractile 
function and /3-adrenergic responsiveness. 15' 16 To 
determine whether T 3 exerted its acute influence 
through binding to the /3-adrenergic receptor with 
resultant cAMP production, we examined myocyte 
contractile function after the addition of proprano- 
lol (a nonselective 13-adrenergic; 25 nmol/L). The 
dose of propranolol used was sufficient to inhibit the 
contractile response of the myocyte to isoproterenol 
(data not shown). This concentration f propranolol 
had no effect on the increase in myocyte contractile 
function after the acute addition of T3. Thus the 
increase in contractile function with T 3 was appar- 
ently not mediated solely through binding to the 
;3-adrenergic receptor. In the next series of experi- 
ments, potential contributory mechanisms for the 
effects of T 3 on myocyte contractile function were 
examined, 
cAMP generation. The focus of this series of 
experiments was to examine whether T 3 influenced 
cAMP generation i  isolated myocytes. The results 
from this series of experiments are summarized in 
Fig. 1. In the presence of T3 alone, cAMP genera- 
tion increased from baseline (no T3) values (39 +_ 8 
fmols/mY0cyte versus 25 _+ 6 fmols/myocyte, r spec- 
tively), although this increase did not reach statisti- 
cal significance (p = 0.17). However, cAMP gener- 
ation increased to 120 _+ 35 fmols/myocyte (p < 
0.05) after ;3-adrenergic receptor stimulation. Fur- 
thermore, in the presence of both T 3 and/3-adren- 
ergic receptor stimulation, cAMP production in- 
creased to 224 _+ 61 fmols/myocyte, which was 
significantly higher than values with /3-adrenergic 
receptor stimula6on alone (p < 0.05). Thus T 3 signif- 
icantly augmented cAMP generation after/3-adrener- 
gic receptor stimulation i  isolated myocytes. 
Na+,K+-ATPase hydrolytic activity. To deter- 
mine whether T 3 modulated global myocyte sar- 
colemmal systems, Na+,K+-ATPase hydrolytic ac- 
tivity wa s measured with use of purified LV 
sarcolemmal preparations. Basal Na+,K+-ATPase 
hydrolytic activity was 2.2 +_ 0.1 /zg/mg of protein 
per hour. This value is consistent with results previ- 
ously obtained by this laboratory with similar LV 
sarcolemmal preparations. 4° Na÷,K+-ATPase hy- 
drolytic activity did not increase in the presence of 
80 pmol/L T 3 (2.3 _+ 0.1/xg/mg of protein per hour, 
p = 0.62). Therefore, in these studies of isolated LV 
sarcolemmal preparations, the acute addition of T 3 
did not directly influence Na+,K+-ATPase hydro- 
lytic activity. 
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Fig. 1. cAMP generation i  normal, isolated myocytes 
(no T3), in presence of 80 pmol/L T3, with/3-adrenergic 
receptor stimulation with isoproterenol (25 nmol/L), and 
in presence of both T3 and/3-adrenergic re eptor stimu- 
lation. In presence of T3, cAMP generation was not 
significantly different from that in untreated myocytes. 
cAMP production i creased significantly with/3-adrener- 
gic receptor stimulation. Finally, in presence of both T 3 
and/3-adrenergic re eptor stimulation, cAMP production 
increased significantly higher than values observed with 
/3-adrenergic receptor stimulation alone. Absolute values 
for cAMP generation are reported in Results section. 
*p < 0.05 versus no T3; #p < 0.05 versus isoproterenol. 
L-type Ca +2 channel currents. L-type Ca +2 chan- 
nel current and voltage relationships were success- 
fully obtained with use of perforated nystatin patch 
clamp techniques in 15 isolated myocytes. The I-V 
relationships for the L-type Ca +2 channel current at 
baseline (no T3), with T 3 alone, with /3-adrenergic 
receptor stimulation, and in the presence of both T 3 
and/3-adrenergic receptor stimulation are shown in 
Fig. 2. The peak L-type Ca +2 channel current com- 
puted for these conditions is summarized in Fig. 3. 
Although T 3 did not significantly increase L-type 
Ca +a channel current density, the voltage at which 
peak Ca +2 channel current was obtained signifi- 
cantly shifted from the baseline value (5.5 _+ 1.4 mV 
versus 9.0 _+ 1.0 mV, p < 0.05). However, no 
difference in the voltage at peak current was ob- 
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Fig. 2. L-type Ca +2 channel I-V relationships obtained 
from 15 isolated myocytes with use of patch clamp micro- 
electrode techniques. In presence of 80 pmol/L T3 alone 
there was no apparent increase in L-type Ca +2 channel 
current, but significant leftward shift was observed for 
voltage at which peak current occurred. /3,Adrenergic 
receptor stimulation with isoproterenol (25 nmol/L) 
caused change in I-V relationship. Specifically, significant 
increase in maximum L-type Ca ÷2 channel current density 
was observed. In presence of both T 3 and /3-adrenergic 
receptor stimulation, further increase in L-type Ca ÷2 
channel current density was observed. Absolute values for 
L-type Ca ÷2 channel current density are shown in Fig. 3. 
Voltages at which peak L-type Ca ÷2 channel current 
occurred are reported in Results section. 
served after/3-adrenergic receptor stimulation alone 
or in the presence of both T 3 and /3-adrenergic 
receptor stimulation (6.0 + 2.9 mV versus 5.6 +-- 2.4 
mV, respectively, p = 0.14). With /3-adrenergic 
receptor stimulation, peak intracellular L-type Ca ÷2 
channel current density increased significantly from 
baseline values. Furthermore, in the presence of 
both T 3 and /3-adrenergic receptor stimulation, an 
additional increase in L-type Ca +2 channel current 
density was observed that was significantly higher 
than that obtained by /3-adrenergic stimulation 
alone (p < 0.05). Therefore in the presence of T 3 
maximum L-type Ca +2 channel current density was 
unchanged, but a significant shift occurred in the 
voltage at which peak current was obtained. Fur- 
thermore, T 3 augmented the L-type Ca +2 channel 
£ 
"d 
10 
,# 
I I No  T 3 
NgVI T3 
1 Isoproterenol 
I I T3 + Isoproterenol 
Fig. 3. Peak intracellular L-type Ca ÷2 channel current 
density (-pA/pF) for isolated myocytes. No change in 
L-type Ca ÷2 channel current density occurred in presence 
of 80 pmol/L T 3. Significant increase in L-type Ca +2 
channel current density occurred after ~-adrenergic re- 
ceptor stimulation with isoproterenol (25 nmol/L). More 
important, in presence of both T 3 and /3-adrenergic re- 
ceptor stimulation, L-type Ca +2 channel current density 
increased to values higher than those with /3-adrenergic 
receptor stimulation alone. *p < 0.05 versus no T3; #p < 
0.05 versus isoproterenol. 
current density with concomitant /3-adrenergic re- 
ceptor stimulation. 
Intraeellular Ca ÷2 measurements.  In a final se- 
ries of experiments, myocyte intracellular Ca +2 was 
measured at baseline, with T 3, with /3-adrenergic 
receptor stimulation, and in the presence of both T 3 
and/3-adrenergic receptor stimulation. Intracellular 
Ca +2 measurements were first obtained in myocytes 
in the quiescent resting state (no electrical stimula- 
tion). Next, myocytes were stimulated at 0.5 Hz and 
steady-state and peak intracellular Ca +2 levels were 
determined. The results from this portion of the 
study are summarized in Table II. In normal myo- 
cytes (no T3), both steady-state and peak intracellu- 
lar Ca +2 levels significantly increased from values in 
the quiescent resting state after initiation of electri- 
cal stimulation (p < 0.05). In the presence of T3, 
steady-state and peak intracellular Ca ÷2 levels in- 
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Table II. Acute effects of incubation with T 3 on myocyte intracellular calcium levels 
Electrical stimulation (0.5 Hz) 
Quiescent state Steady state Peak level 
Calcium level (nmol/L) 
No T 3 110.2 _+ 2.8 136.1 _+ 3.1 159.2 _+ 3.9 
80 pmol/L T3 alone 106.3 _+ 3.6 135.1 +_ 4.2 159.6 _+ 5.7 
25 nmol/L isoproterenol a one 109.4 ÷ 4.8 142.7 _+ 7.4 171.7 +_ 8.3* 
80 pmol/L T 3 plus 25 nmol/L isoproterenol 117.2 _+ 4.7 158.5 _+ 7.5* 189.9 +_ 8.4*? 
No. of myocytes 
No T 3 47 47 47 
25 nmol/L isoproterenol 18 18 18 
80 pmol/L T 3 23 23 23 
80 pmol/L T 3 plus 25 nmol/L isoproterenol 19 19 19 
Values presented as mean plus or minus standard error of mean. 
*p < 0.05 versus no T 3. 
tp < 0.05 versus isoproterenol. 
creased from quiescent resting state values, but 
these values were not different from those in un- 
treated myocytes. After ]3-adrenergic receptor stim- 
ulation, peak intracellular Ca ÷2 levels were signifi- 
cantly greater than peak intracellular Ca ÷2 levels in 
untreated myocytes (p < 0.05). Furthermore, peak 
intracellular Ca ÷2 levels were significantly higher in 
the presence of both T 3 and ]3-adrenergic receptor 
stimulation compared with those with ]3-adrenergic 
receptor stimulation alone (p < 0.05). Thus T3 
significantly augmented intracellular Ca ÷2 levels 
with concomitant ]3-adrenergic receptor stimulation. 
Discussion 
Past reports have suggested that the acute adminis- 
tration of T3 may improve indices of LV pump per- 
formance and myocyte contractile function. 1316'46sl 
However, the contributory cellular and molecular 
mechanisms responsible for these acute effects of T 3 
on LV and myocyte function remain incompletely 
understood. Accordingly, the present study investi- 
I 
gated whether T3 would influence fundamental de- 
terminant~ of myocyte contractile performance. 
Specifically, sarcolemmal transduction systems, in- 
tracellula~ cAMP generation, and intracellular Ca +2 
levels were examined in the presence of T 3. The 
important I and unique findings from the present 
study were twofold. First, T 3 caused a significant 
shift in th~ activation voltage required for maximum 
L-type Ca +2 channel current density. Thus this 
leftward shift in the activation voltage of the L-type 
Ca +2 channel may have prolonged channel opening 
periods a0d thereby enhanced myocyte contractile 
processes. I In the presence of both T 3 and ;3-adren- 
erglc receptor stimulation, intracellular cAMP gen- 
eration was increased, L-type Ca +2 channel current 
density was enhanced and myocyte peak intracellu- 
lar Ca +z levels were elevated. Consequently, one 
contributory mechanism for the beneficial effects of 
T 3 after ]3-adrenergic receptor stimulation may be a 
result of phosphorylation f the L-type Ca --2 chan- 
nel with a subsequent increase in Ca ÷2 availability to 
the contractile apparatus. Therefore the present 
study provides unique evidence to suggest that T 3 
has specific and selective effects on steady-state 
myocyte ionic homeostasis and intracellular events 
after ]3-adrenergic receptor stimulation. 
The direct effects of acute administration f T 3 on 
LV pump performance have been the focus of 
several recent investigations. 13' 14, 46-51 For example, 
Dyke and colleagues s° demonstrated that T 3 im- 
proved LV peak developed pressure after global 
ischemia in isolated rabbit heart preparations. 
Moreover, Wechsler and colleagues 4 demonstrated 
that T 3 administration significantly improved the 
preload recruitable stroke-work relationship in pigs 
after cardiopulmonary b pass. In patients, it has 
been reported that acute administration f T 3 at the 
termination of cardiopulmonary b pass results in a 
decreased requirement for inotropic therapy. 13 The 
present study, as well as a recent report, 15 demon- 
strated that T 3 has direct effects on myocyte con- 
tractile performance. The present study builds on 
these past studies by identifying the potential mech- 
anisms responsible for the beneficial effects of T 3 on 
LV and myocyte function. Specifically, in the pres- 
ence of T3, a shift in the activation voltage at peak 
current for the L-type Ca +2 channel was observed. 
Further, in the presence of both T 3 and ]3-adrener- 
gic receptor stimulation an increase was observed in 
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L-type Ca +2 channel current density, cAMP produc- 
tion, and intracellular Ca +2 level within the myo- 
cyte. 
The classic mechanism of action for T 3 has been 
described to occur through the interaction with 
nuclear receptors and subsequent modifications in 
protein expression and translation. 6-1° However, in 
the present study, as well as in past reports, the 
effects of T 3 have been observed to have an imme- 
diate onset of action with respect to LV and myocyte 
performance. Therefore an alternative mechanism 
for the acute actions of T 3 may be through modula- 
tion in the activity of myocyte sarcolemmal sys- 
tems. 2°-25 Previous reports have shown that T 3 in- 
creased Na ÷ channel activity, enhanced the 
transport of small molecules, and augmented sar- 
colemmal Ca+2-ATPase activity. 2°' 24, 25,52 For ex- 
ample, Rudinger and associates 24reported an in- 
crease in basal Ca+2-ATPase actiyity in normal 
rabbit sarcolemma in the presence of T 3. In addi- 
tion, Craelius, Green, and Harris 52 reported an 
acute increase in the peak influx of Na + and in- 
creased duration of the action potential in a rat 
myocyte preparation after the addition of T 3. These 
past reports provide evidence to suggest hat T 3 
directly modulates myocyte sarcolemmal func- 
tion. z°-25 The present study demonstrated that T 3 
directly influenced specific sarcolemmal receptor 
systems, which included the L-type Ca +2 channel 
and the/3-adrenergic receptor system. Therefore the 
present study provides evidence to suggest hat the 
alterations in LV and myocyte function after T 3 
administration were a direct result of modulation of 
myocyte sarcolemmal systems. 
A common method to improve contractile state is 
through stimulation of the /3-adrenergic receptor 
system. After binding of an agonist o the/3-adren- 
ergic receptor, a cascade of events occurs that 
includes modulation of a G protein complex, stim- 
ulation of adenylate cyclase, and subsequent pro- 
duction of cAMP. a9, 30 The mechanisms of action for 
cAMP within the myocyte include phosphorylation 
of the sarcolemmal L-type Ca +2 channel and phos- 
pholamban on the sarcoplasmic reticulum. 29' 3o Thus 
cAMP is an important determinant of intracellular 
Ca ÷2 availability to the contractile apparatus within 
the myocyte. The present study demonstrated that 
in the presence of T3, myocyte/3-adrenergic espon- 
siveness was significantly enhanced. In addition, in 
the presence of T3, cAMP production after/3-adren- 
ergic receptor stimulation was significantly aug- 
mented. However, T 3 alone did not significantly 
increase cAMP production. Important conclusions 
from this portion of the study were twofold. First, 
the direct effects of T 3 on myocyte contractile function 
in the absence of/3-adrenergic receptor stimulation 
appeared to be independent of cAMP-mediated 
events. Second, T 3 augmented cAMP production in 
response to /3-adrenergic receptor stimulation 
within the myocyte. Therefore the findings of the 
present study provide a potential molecular mecha- 
nism for the past clinical observation of reduced 
inotropic requirements after T 3 administration. 13 
Several reports have suggested that T 3 may influ- 
ence the myocyte sarcolemmal Na+,K+-ATPase sys- 
tem. 26-28 For example, Philipson and Edelman 26 
demonstrated an increase in Na+,K+-ATPase activ- 
ity in myocardial homogenates after chronic treat- 
ment with T 3 in rats. Similar studies have suggested 
that Na+,K+-ATPase activity and density increased 
after chronic exposure to T3. 28 The present study 
examined the immediate ffects of T3 on Na+,K +- 
ATPase hydrolytic activity in the presence of T3. 
Thus the present study suggests that the immediate 
effects of T 3 on myocyte contractile performance 
were not mediated by direct effects on Na+,K +- 
ATPase hydrolytic activity. 
The L-type Ca +2 channel is an important sar- 
colemmal receptor system with respect o the mod- 
ulation of Ca +2 entry into the myocyte and serves to 
trigger elease of Ca +2 from the sarcoplasmic retic- 
ulum. 32 Therefore the total amount of Ca +2 enter- 
ing the myocyte through each L-type Ca +2 channel 
during channel opening periods is a fundamental 
determinant of the total amount of Ca +2 available 
to the contractile apparatus9 2 The total amount of 
Ca +2 entering the myocyte through the L-type Ca +2 
channel is directly proportional to the peak current 
and the duration that the L-type Ca +2 channel 
remains open. 53 In the present study, a significant 
shift was observed in the voltage at which peak 
L-type Ca +2 channel current occurred after T 3 
administration. This immediate ffect of T 3 on the 
L-type Ca +2 channel I-V relation may have caused 
increased Ca +2 entry through the channel with an 
augmentation of Ca +2 release from the sarcoplas- 
mic reticulum and subsequent enhancement of myo- 
filament crossbridging. Therefore one potential 
mechanism for the direct effects of T 3 on myocyte 
contractile performance may be modulation of the 
L-type Ca +2 channel opening periods. Future stud- 
ies directed at more careful quantitation of L-type 
Ca +2 channel gating properties, specifically the 
probability of channel opening periods, would be 
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necessary to more carefully address this issue./3-Ad- 
renergic receptor stimulation with subsequent 
cAMP production has been previously demon- 
strated to cause phosphorylation f the L-type Ca +2 
channels and thereby increase peak L-type Ca +2 
channel current. 32' 53 Consistent with this past ob- 
servation, the present study demonstrated that/3-ad- 
renergic receptor stimulation significantly increased 
L-type Ca ~2 channel current. More important, in 
the presence of both T 3 and/3-adrenergic receptor 
stimulation, L-type Ca +2 channel current increased 
further from values with/3-adrenergic receptor stim- 
ulation alone. Results from the present study dem- 
onstrated that T 3 augmented/3-adrenergic receptor- 
stimulated cAMP generation. Accordingly, apotential 
mechanism for the augmentation i L-type Ca +2 
channel current density in the presence of both T 3 
and/3-adrenergic receptor stimulation was probably 
increased phosphorylation f the L-type Ca +2 chan- 
nel itself. 
A final result from the activation of the/3-adren- 
ergic receptor system or increased L-type Ca +2 
channel current is an elevation in myocyte intracel- 
lular Ca +2 content. In the present study intracellular 
Ca +2 levels were determined in isolated myocytes in 
real time with use of the Ca+2-specific dye, fura 
2/acetomethoxy ester. 44 Through this approach it 
could be determined whether T 3 alone directly 
modulated myocyte intracellular Ca +2 levels. Re- 
sults from the present study demonstrated that no 
significant: change in intracellular Ca +2 levels oc- 
curred after the addition of T 3. These findings are 
consistent with those of a past report by Wicomb 
and associates 54that demonstrated that no change 
in intracellular Ca +2 concentrations occurred in the 
presence of T3. One potential reason for the in- 
crease in myocyte contractile function after the 
addition of T 3 in this isolated myocyte model may be 
that the standard culture medium does not contain 
T 3. Thus the increase in myocyte contractile func- 
tion after the addition of T 3 may be a result of the 
normalization of T 3 concentrations found in plasma. 
In the present study, myocyte peak intracellular 
Ca ÷2 levels were significantly increased after/3-ad- 
renergic receptor stimulation. This finding is consis- 
tent with the downstream effects of /3-adrenergic 
receptor stimulation, z9'3° More important, in the 
presence of both T 3 and /3-adrenergic receptor 
stimulation, myocyte intracellular Ca +2 levels in- 
creased significantly higher than those values ob- 
tained with/3-adrenergic receptor stimulation alone. 
These findings demonstrated for the first time that 
T3 has the capacity to directly regulate intracellular 
Ca +2 availability to the contractile apparatus after 
/3-adrenergic receptor stimulation. Therefore a con- 
tributory molecular mechanism for the improved 
myocyte /3-adrenergic responsiveness in the pres- 
ence of T 3 is increased myocyte intracellular Ca +2 
availability. 
Fundamental pproaches for improving LV pump 
function after cardiopulmonary b pass and in the 
critical care setting require manipulation of the 
/3-adrenergic receptor transduction system. In 
present clinical practice, the therapeutic approach 
to increasing LV contractile state is through the use 
of/3-adrenergic receptor agonists or phosphodies- 
terase inhibitors, both of which result in increased 
cAMP content within the myocyte. However, long- 
term/3-adrenergic re eptor stimulation is associated 
with a significant number of complications, which 
include receptor desensitization and downregula- 
tion, arrhythmias, and hemodynamic instabilityY' 56 
Therefore a continuing area of research is the 
pursuit of unique and alternative pharmacologic 
therapy for improving LV contractile performance. 
The present study demonstrated that T 3 improved 
myocyte contractile performance and was associated 
with modulation of the L-type Ca +2 channel. Fur- 
thermore, T3 augmented myocyte /3-adrenergic re- 
ceptor transduction and subsequent Ca +2 availabil- 
ity to the contractile apparatus. Therefore the 
present study suggests that T 3 may provide a 
unique therapeutic modality, particularly as an 
adjunct to conventional /3-adrenergic receptor 
agonist herapy. 
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Discussion 
Dr. Dimitri Novitzky (Tampa, Fla.). It is an honor to 
discuss this manuscript because I have been involved since 
1983 in initial developments for the clinical indications of 
the use of triiodothyronine for nonthyroid conditions. The 
rapid reduction of plasma free T 3 has been observed in 
acute stress states with concomitant elevated plasma 
catecholamine levels. The tissue T 3 synthesis is markedly 
impaired and the mono-deiodination f thyroxine results 
in the production of reverse T3, a metabolically inactive 
compound. Experimental data have shown depletion of 
intracellular T 3 that is associated with abnormalities in the 
calcium metabolism, down regulation of beta receptors, 
and uncoupling of adenylate cyclase. As patients require 
higher doses of exogenous catecholamines, tachyphylaxis 
complicates the clinical picture, initiating the downward 
spiral course of multiorgan failure and death. 
This has been observed in several clinical conditions 
such as in brain death, in heart operations with cardiopul- 
monary bypaSs, in myocardial infarction, in severe cardiac 
failure, and in all shock states. 
The data obtained after the induction of experimental 
brain death in animals how that there is a rapid depletion 
of plasma free T 3 and it is associated with a catecholamine 
storm, thus resulting in diffuse structural myocardial in- 
jury and depletion of high-energy phosphates and lactate 
accumulation. Replacement of triiodothyronine in brain- 
dead animals rapidly restored the aerobic metabolism, 
correcting the tissue lactic acidosis and high-energy phos- 
phate levels. Rapid recovery of myocardial dysfunction 
was observed in an ex vivo model no different from that of 
hearts procured from live animals. Today, T 3 has become 
a therapeutic modality in organ transplantation. 
We administered triiodothyronine for the first time in 
1986 to a patient dependent on cardiopulmonary b pass 
used for emergency valve replacement because of bacte- 
rial endocarditis and sepsis. The patient was supported by 
cardiopulmonary b pass, dependent on high-dose inotro- 
pic support, and remained in ventricular fibrillation de- 
spite all therapeutic interventions. After T3 administra- 
tion, cardiac recovery was observed within minutes, the 
heart converted to sinus rhythm, and the inotropic support 
was rapidly reduced. The patient was later discharged 
home. 
This clinical observation led us to our extensive xper- 
imental work in animals, in which we observed recovery of 
these rapid high-energy phosphates and prevention of 
tissue lactase in baboons. 
We have currently administered T 3 to patients with 
high-risk conditions, and in our experience of 134 patients 
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with a mean estimated mortality rate of 29% the mortality 
has been reduced by 73%. 
The authors have clearly shown that the rapid extranu- 
clear effects of T 3 bypass the deoxyribonucleic a id- 
ribonucleic acid-protein synthesis and have observed an 
increment of the calcium availability to the sarcomeres 
and the synergistic effects with beta receptors enhancing 
the contractile process in the isolated myocyte. Obviously 
further studies are required to elucidate the interaction of
the myocyte, the endothelium, the autonomic system, and 
the whole components of blood, not only within the heart 
but also at the systemic level and as concerns other organs. 
My first question is this: have the authors looked at the 
prolonged effects of adrenergic stimulation of the isolated 
myocyte? Has tachyphylaxis been observed and have the 
authors tried to reverse this by T37 
Second, because T3 works via calcium fluxes and there 
is rapid recompartmentalization of free ionized calcium 
mainly within the sarcoplasmic reticulum, would the au- 
thors speculate that pretreatment with T3 before an 
ischemic event might prevent or reduce the reperfusion 
injury such as observed in the stunned myocardium? 
Finally, because the beneficial effect of T 3 on the 
cardiovascular system directly affects the contractile state 
of the heart and reduces the systemic vascular resistance, 
would the authors consider expanding their study to look 
at isolated myocytes procured from peripheral smooth 
muscle arterioles and the interaction ofT 3 with vasoactive 
agents? 
I would like to congratulate he authors once more for 
this excellent work in which molecular biology and clinical 
observations go hand in hand. 
Dr. Walker. In this model of isolated myocytes we have 
looked at the effects of T 3 independent of neurohormonal 
influences and independent of loading conditions. We 
have actually examined the changes in calcium levels, but 
we have not examined fluxes in calcium and whether these 
are affected by ischemia. The model that we use to 
examine myocytes that is more clinically relevant to 
patients with dilated cardiomyopathy is not an ischemic 
model, it is a model of dilated cardiomyopathy in which 
there is no ischemia. Therefore we have not looked at 
those problems. 
Finally, we have not looked at the effects of T 3 on 
loading conditions specifically because that has been done 
by other investigators. The purpose of these studies was to 
see whether T3 had its effects directly at the level of the 
myocytes. 
Dr. Andrew S. Weehsler (Richmond, Va.). How do the 
authors explain that in these isolated cell suspensions they 
have always seen a positive inotropic response? This 
differs from results of most of the studies in whole organs 
in which it has been difficult to demonstrate a positive 
inotropic response xcept after ischemia. 
Dr. Walker. The positive response to T 3 in the 
isolated myocytes used in our studies was measured in 
an environment devoid of thyroid hormone. This mim- 
ics the low T 3 state seen with ischemia where other 
investigators have seen a positive inotropic response in 
whole organs. 
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